In addition, particular peptides can be engineered to attack cancer cells and prevent tumor progression
Evolving Role of GLP-1 Therapies in Liver Disease
#PharmaNews #PharmaResults #EarningsUpdate #IndianPharma #PharmaUpdates #Harshal #PharmawithHJ #HJ Gland Pharma FY25 Results: Strong Margins, 31 Product Launches Gland Pharma Limited FY25 Results: Margins Hold Strong, Strategy Gathers Steam Financial Highlights: - FY25 Revenue: 5,617 Cr (1% YoY) - EBITDA Margin: 1,269 Cr (5% YoY) | Margin 23% - PAT: 698 Cr (10% YoY) | Margin at 12% - Dividend: 18/share final dividend recommended Business Highlights: - 31 product launches in FY25, including new molecules like Latanoprost & Dexamethasone - 32 ANDA approvals, 24 filings U.S
Platelet oxidative stress and systemic inflammation in chronic spontaneous urticaria
lowers blood pressureLowers blood pressure and increased blood flow and vascularity
Sergey Terushkin, MD, FACS Dr